Theranos (2015): Sanctions and shutdown

Internal and later public records showed that many tests offered to patients were run on third-party analyzers, sometimes after diluting small samples, while the company’s own devices handled a narrower set. That gap is the factual core of the later fraud cases. Carreyrou’s October 2015 article, followed by more Journal reporting, forced the company into a defensive public posture. CMS inspected the Newark, California laboratory and in 2016 imposed sanctions, including a ban on Holmes’s operating labs for a period.

The FDA and CMS files, plus later SEC charges in March 2018, moved the story from a magazine dispute into the enforcement docket. The company dissolved in 2018 as the criminal case was prepared. Holmes’s trial (2021–2022) focused on what investors were told about technology, pharmaceutical-company validation, and the Department of Defense. The jury convicted on investor-fraud counts and acquitted or hung on others, including patient-related wire-fraud counts.

Balwani was tried separately in 2022 and convicted on all counts he faced, including investor and patient-related fraud. The split outcomes are part of the public record and are often flattened in casual retellings. Theranos is not an unsolved scientific puzzle. Courts treated the investor representations as false. Remaining argument is about sentence length, appeal points, and how much patient harm the Holmes verdict legally found.